Oncolytics Biotech (TSE:ONC) Stock Price Up 18.2% - What's Next?

Oncolytics Biotech Inc. (TSE:ONC - Get Free Report)'s stock price was up 18.2% during trading on Tuesday . The stock traded as high as C$1.69 and last traded at C$1.62. Approximately 747,191 shares were traded during mid-day trading, an increase of 455% from the average daily volume of 134,529 shares. The stock had previously closed at C$1.37.

Wall Street Analysts Forecast Growth

Separately, Jones Trading cut shares of Oncolytics Biotech from a "strong-buy" rating to a "hold" rating in a research report on Friday, May 16th.

Oncolytics Biotech Stock Performance

The company has a market capitalization of C$123.32 million, a PE ratio of -4.46 and a beta of 1.35. The business's 50-day moving average is C$0.81 and its 200-day moving average is C$0.94. The company has a debt-to-equity ratio of 11.75, a quick ratio of 8.86 and a current ratio of 2.99.

Oncolytics Biotech Company Profile

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.